Sarcopenia Abdominal Muscle Mass Index Assessment Informs Surgical Decision-Making in Displaced Fractures of the Femoral Neck

肌少症腹肌质量指数评估指导股骨颈移位性骨折的手术决策

阅读:1

Abstract

Background: Displaced femoral neck fractures (FNFs) can be treated with hemiarthroplasty (HA) or total hip arthroplasty (THA), with THA typically offered to fitter patients. Sarcopenia increases complications and mortality after hip arthroplasty. The psoas muscle-L3 vertebra ratio (PML3) is a sarcopenia marker. This study evaluated PML3's role in predicting postoperative outcomes and guiding surgical decision-making. Methods: A retrospective study was conducted at a single centre between January 2021 and December 2024. PML3 was measured on computed tomography (CT) at the L3 vertebra level for patients with displaced FNFs, comparing postoperative outcomes between HA and THA cohorts. Results: Eighty-three patients (fifty-seven female, twenty-six male) were analysed. Forty-three underwent THA, and forty underwent HA. Postoperative complications were higher in HA patients (48% vs. 21%, p = 0.019), with lower 30-day survival (90% vs. 98%). Median PML3 in the HA group was 0.70 mm(2) (IQR: 0.47-1.47), lower than in the THA group (1.34 mm(2), IQR: 1.00-1.78, p = 0.002). However, PML3 values for patients that suffered complications (irrespective of surgical decision) were essentially the same; HA, 0.57 mm(2) (IQR: 0.43-1.83); THA 0.56 mm(2) (IQR: 0.41-1.05, p = 0.847). ROC analysis showed PML3 as an acceptable predictor of postoperative complications, with an AUC of 0.71. Conclusions: Lower PML3 values correlate with higher postoperative complications and mortality following THA or HA for displaced FNFs, confirming its role as a prognostic marker. Some THA complications in low-PML3 patients might have been avoided by selecting less invasive HA, suggesting THA should be reserved for those with greater muscle reserves.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。